What is it about?
Even with treatment, a pro-inflammatory state persists. A network of cytokines and chemokines in CIDP maintains the inflammation in an orchestral manner. Standard therapy alone cannot correct the impaired T-reg function.
Featured Image
Why is it important?
Early, high-dose daily vitamin D supplementation, when serum 25(OH) levels reach 50 ng/ml or above, can suppress inflammation even during periods of apparent clinical improvement. 1,25(OH)2D3 is a target for the involved, immune-activating, pro-inflammatory agents, particularly improving Treg cell function. The pathophysiological basis for this add-on therapy is well-established. However, it is not reflected in the guidelines of many neurological societies.
Perspectives
The use of serum neurofilament light chains (NfL) and glial fibrillary acidic protein (GFAP) allows for monitoring the dynamics of the disease process. The intensity and duration of therapy are determined by these two biomarkers. Not only during the period of standard pulsed therapy but also in the intervals between treatment courses, vitamin D supplementation is key to mitigating immune dysregulation.
Hans-Klaus Goischke
Read the Original
This page is a summary of: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Extension of Standard Therapy With Vitamin D Supplementation Based on Pathophysiology, Neurology and Neuroscience, August 2025, SciVision Publishers LLC,
DOI: 10.33425/2692-7918.1104.
You can read the full text:
Contributors
The following have contributed to this page
